A Tough Year for Gaucher Sufferers


By Laurie Stern

Published August 11, 2010, issue of August 20, 2010.
  • Print
  • Share Share

It has been a year filled with anxiety, fear and disappointment for sufferers from Gaucher disease, who are continuing to deal with the fallout from last year’s shutdown of a pharmaceutical plant.

In June 2009, Genzyme, the manufacturer of Cerezyme, then the only approved treatment for type 1 Gaucher disease, was forced to shut down the Allston, Mass., manufacturing plant where the drug was produced after a virus contaminated the facility.

A year later there are still acute shortages of Cerezyme. Although another pharmaceutical company’s alternative drug was rushed to market, there are waitlists for that therapy.

“It’s definitely been the hardest year,” said Stuart Berman, a Gaucher patient and co-chairman of New York University Langone Medical Center’s Gaucher support group. “Most patients were very scared and very worried.”

In Gaucher disease, lipids accumulate in the organs due to the absence of an enzyme that breaks down the fatty substances. If not treated, symptoms of Gaucher disease include anemia, fatigue, bone pain and swelling of the liver or spleen.

Patients who relied on Cerezyme for their bi-monthly enzyme-replacement therapy rapidly had to choose an alternative course of action in order to maintain their health.

“It was quite unsettling,” said Dr. Gregory Pastores, a National Gaucher Foundation board member and associate professor at New York University Medical Center. “There was a lot of residual loyalty to Genzyme because they were the only company in the beginning. People were a little bit surprised that this could happen.”

Fortunately for Gaucher sufferers, Shire pharmaceutical was in phase three of Food and Drug Administration testing on its own enzyme-replacement therapy called VPRIV (velaglucerase alfa). VPRIV was put on accelerated application and released 18 months ahead of its target date, said Shire spokeswoman Jessica Cotrone.

“We were lucky that we had batches left over from the clinical trial,” Cotrone said. “We put some things on hold and made sure VPRIV was front and center at our manufacturing facilities. We felt very fortunate we were able to do that and provide something to patients in their time of need.”

Gaucher disease is an autosomal recessive disease and is estimated to occur in one in 20,000 live births, with a carrier rate of 1 in 10 among the Ashkenazi Jewish population, according to the National Gaucher Foundation.

Though most patients were able to get by after the Genzyme contamination by using their own stored vials of Cerezyme or switching to VPRIV, today the Gaucher community still remains uncertain regarding treatment consistency.

While doses of Cerezyme will be increasing in the coming months, they will not be at prime availability until the fourth quarter of the year, said Genzyme spokeswoman Lori Gorski. And because Shire was asked by the FDA to unexpectedly dispense its supply of VPRIV after the Genzyme contamination, Shire now has a waitlist of new patients wondering when the drug will become available to them, as it takes approximately six months to create a single batch of the treatment.

As patients have abandoned Cerezyme in the wake of Genzyme’s contamination crisis, many have switched over to VPRIV, which boasts a shorter infusion time. But oral treatment options are also available. A new therapy from Israeli drug company Protalix Biotherapeutics is currently in clinical trials and is expected to be marketed in the United States by Pfizer.

The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.

Find us on Facebook!
  • “Everything around me turns orange, then a second of silence, then a bomb goes off!" First installment of Walid Abuzaid’s account of the war in #Gaza:
  • Is boredom un-Jewish?
  • Let's face it: there's really only one Katz's Delicatessen.
  • "Dear Diaspora Jews, I’m sorry to break it to you, but you can’t have it both ways. You can’t insist that every Jew is intrinsically part of the Israeli state and that Jews are also intrinsically separate from, and therefore not responsible for, the actions of the Israeli state." Do you agree?
  • Are Michelangelo's paintings anti-Semitic? Meet the Jews of the Sistine Chapel: http://jd.fo/i4UDl
  • What does the Israel-Hamas war look like through Haredi eyes?
  • Was Israel really shocked to find there are networks of tunnels under Gaza?
  • “Going to Berlin, I had a sense of something waiting there for me. I was searching for something and felt I could unlock it by walking the streets where my grandfather walked and where my father grew up.”
  • How can 3 contradictory theories of Yiddish co-exist? Share this with Yiddish lovers!
  • "We must answer truthfully: Has a drop of all this bloodshed really helped bring us to a better place?”
  • "There are two roads. We have repeatedly taken the one more traveled, and that has made all the difference." Dahlia Scheindlin looks at the roots of Israel's conflict with Gaza.
  • Shalom, Cooperstown! Cooperstown Jewish mayor Jeff Katz and Jeff Idelson, director of the National Baseball Hall of Fame, work together to oversee induction weekend.
  • A boost for morale, if not morals.
  • Mixed marriages in Israel are tough in times of peace. So, how do you maintain a family bubble in the midst of war? http://jd.fo/f4VeG
  • Despite the escalating violence in Israel, more and more Jews are leaving their homes in Alaska to make aliyah: http://jd.fo/g4SIa
  • from-cache

Would you like to receive updates about new stories?

We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.